Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
WAVE Life Sciences Ltd has a consensus price target of $18.81 based on the ratings of 16 analysts. The high is $36 issued by Truist Securities on November 12, 2024. The low is $7 issued by SVB Leerink on December 14, 2022. The 3 most-recent analyst ratings were released by Wedbush, Raymond James, and Cantor Fitzgerald on June 23, 2025, June 11, 2025, and April 29, 2025, respectively. With an average price target of $14 between Wedbush, Raymond James, and Cantor Fitzgerald, there's an implied 101.15% upside for WAVE Life Sciences Ltd from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/23/2025 | Buy Now | 158.62% | Wedbush | Yun Zhong38% | $18 → $18 | Reiterates | Outperform → Outperform | Get Alert |
06/11/2025 | Buy Now | 101.15% | Raymond James | Michael Freeman16% | → $14 | Assumes | → Outperform | Get Alert |
04/29/2025 | Buy Now | 43.68% | Cantor Fitzgerald | Steven Seedhouse57% | → $10 | Initiates | → Overweight | Get Alert |
03/26/2025 | Buy Now | 216.09% | HC Wainwright & Co. | Andrew Fein60% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
03/05/2025 | Buy Now | 216.09% | HC Wainwright & Co. | Andrew Fein60% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
02/25/2025 | Buy Now | 273.56% | Jefferies | Roger Song35% | → $26 | Initiates | → Buy | Get Alert |
11/21/2024 | Buy Now | 216.09% | Mizuho | Salim Syed44% | $19 → $22 | Maintains | Outperform | Get Alert |
11/13/2024 | Buy Now | 216.09% | HC Wainwright & Co. | Andrew Fein60% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
11/12/2024 | Buy Now | 417.24% | Truist Securities | Joon Lee77% | $17 → $36 | Maintains | Buy | Get Alert |
11/04/2024 | Buy Now | 216.09% | B. Riley Securities | Madison El-Saadi28% | $19 → $22 | Maintains | Buy | Get Alert |
10/31/2024 | Buy Now | 216.09% | HC Wainwright & Co. | Andrew Fein60% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
10/21/2024 | Buy Now | 115.52% | RBC Capital | Luca Issi44% | $7 → $15 | Maintains | Sector Perform | Get Alert |
10/17/2024 | Buy Now | 144.25% | JP Morgan | Eric Joseph44% | $13 → $17 | Maintains | Overweight | Get Alert |
10/17/2024 | Buy Now | 216.09% | HC Wainwright & Co. | Andrew Fein60% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
10/16/2024 | Buy Now | 216.09% | Raymond James | Steven Seedhouse57% | $13 → $22 | Upgrade | Outperform → Strong Buy | Get Alert |
10/16/2024 | Buy Now | 216.09% | Wells Fargo | Tiago Fauth46% | $11 → $22 | Maintains | Overweight | Get Alert |
10/16/2024 | Buy Now | 216.09% | Leerink Partners | Mani Foroohar50% | $20 → $22 | Maintains | Outperform | Get Alert |
10/04/2024 | Buy Now | 0.57% | RBC Capital | Luca Issi44% | $5 → $7 | Maintains | Sector Perform | Get Alert |
10/03/2024 | Buy Now | 172.99% | B. Riley Securities | Madison El-Saadi28% | $11 → $19 | Maintains | Buy | Get Alert |
09/27/2024 | Buy Now | 86.78% | JP Morgan | Eric Joseph44% | $10 → $13 | Reinstates | Overweight → Overweight | Get Alert |
09/25/2024 | Buy Now | 129.89% | Jones Trading | Catherine Novack32% | $12 → $16 | Maintains | Buy | Get Alert |
09/25/2024 | Buy Now | 216.09% | HC Wainwright & Co. | Andrew Fein60% | $15 → $22 | Maintains | Buy | Get Alert |
09/19/2024 | Buy Now | 58.05% | B. Riley Securities | Madison El-Saadi28% | → $11 | Initiates | → Buy | Get Alert |
09/09/2024 | Buy Now | 43.68% | JP Morgan | — | → $10 | Initiates | → Overweight | Get Alert |
08/09/2024 | Buy Now | 72.41% | Jones Trading | Catherine Novack32% | → $12 | Initiates | → Buy | Get Alert |
06/26/2024 | Buy Now | 115.52% | HC Wainwright & Co. | Andrew Fein60% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
06/25/2024 | Buy Now | 172.99% | Mizuho | Salim Syed44% | $19 → $19 | Reiterates | Outperform → Outperform | Get Alert |
05/15/2024 | Buy Now | 58.05% | Wells Fargo | Tiago Fauth46% | → $11 | Initiates | → Overweight | Get Alert |
04/01/2024 | Buy Now | 144.25% | Truist Securities | Joon Lee77% | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
03/12/2024 | Buy Now | 172.99% | Mizuho | Salim Syed44% | $10 → $19 | Maintains | Buy | Get Alert |
03/07/2024 | Buy Now | -28.16% | RBC Capital | Luca Issi44% | $5 → $5 | Reiterates | Sector Perform → Sector Perform | Get Alert |
03/07/2024 | Buy Now | 115.52% | HC Wainwright & Co. | Andrew Fein60% | $8 → $15 | Maintains | Buy | Get Alert |
12/19/2023 | Buy Now | 72.41% | Leerink Partners | Mani Foroohar50% | → $12 | Upgrade | Market Perform → Outperform | Get Alert |
08/04/2023 | Buy Now | 14.94% | HC Wainwright & Co. | Andrew Fein60% | → $8 | Reiterates | Buy → Buy | Get Alert |
07/05/2023 | Buy Now | 0.57% | Raymond James | Steven Seedhouse57% | → $7 | Initiates | → Outperform | Get Alert |
06/23/2023 | Buy Now | 144.25% | Truist Securities | Joon Lee77% | → $17 | Reiterates | Buy → Buy | Get Alert |
05/24/2023 | Buy Now | 43.68% | Mizuho | Salim Syed44% | $13 → $10 | Maintains | Buy | Get Alert |
05/24/2023 | Buy Now | 14.94% | HC Wainwright & Co. | Andrew Fein60% | → $8 | Reiterates | Buy → Buy | Get Alert |
05/04/2023 | Buy Now | -28.16% | RBC Capital | Luca Issi44% | → $5 | Reiterates | → Sector Perform | Get Alert |
04/14/2023 | Buy Now | 86.78% | Mizuho | Salim Syed44% | → $13 | Reiterates | → Buy | Get Alert |
03/23/2023 | Buy Now | 14.94% | HC Wainwright & Co. | Andrew Fein60% | → $8 | Reiterates | → Buy | Get Alert |
12/14/2022 | Buy Now | 0.57% | SVB Leerink | Mani Foroohar50% | $2 → $7 | Maintains | Market Perform | Get Alert |
11/11/2022 | Buy Now | -28.16% | RBC Capital | Luca Issi44% | $8 → $5 | Maintains | Sector Perform | Get Alert |
The latest price target for WAVE Life Sciences (NASDAQ:WVE) was reported by Wedbush on June 23, 2025. The analyst firm set a price target for $18.00 expecting WVE to rise to within 12 months (a possible 158.62% upside). 27 analyst firms have reported ratings in the last year.
The latest analyst rating for WAVE Life Sciences (NASDAQ:WVE) was provided by Wedbush, and WAVE Life Sciences reiterated their outperform rating.
The last upgrade for WAVE Life Sciences Ltd happened on October 16, 2024 when Raymond James raised their price target to $22. Raymond James previously had an outperform for WAVE Life Sciences Ltd.
There is no last downgrade for WAVE Life Sciences.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of WAVE Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for WAVE Life Sciences was filed on June 23, 2025 so you should expect the next rating to be made available sometime around June 23, 2026.
While ratings are subjective and will change, the latest WAVE Life Sciences (WVE) rating was a reiterated with a price target of $18.00 to $18.00. The current price WAVE Life Sciences (WVE) is trading at is $6.96, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.